Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
To investigate the pharmacokinetic characteristics of POL7080 co-administered with SoC during
10 to 14 days of treatment in VAP patients due to suspected or documented Pseudomonas
aeruginosa infection